{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:08:21Z","timestamp":1770833301051,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81673834"],"award-info":[{"award-number":["81673834"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fundamental Research Funds for the Central Public Welfare Research Institutes","award":["GH201920"],"award-info":[{"award-number":["GH201920"]}]},{"name":"National Key Technology R&D Program of China","award":["2019ZX09731002"],"award-info":[{"award-number":["2019ZX09731002"]}]},{"name":"Key Laboratory of Beijing for Identification and Safety Evaluation of Chinese Medicine"},{"DOI":"10.13039\/501100002418","name":"Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences","doi-asserted-by":"publisher","award":["BZ0328"],"award-info":[{"award-number":["BZ0328"]}],"id":[{"id":"10.13039\/501100002418","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Nucleic Acids"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.omtn.2019.12.023","type":"journal-article","created":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T01:29:54Z","timestamp":1578619794000},"page":"890-904","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["A Discovery of Clinically Approved Formula FBRP for Repositioning to Treat HCC by Inhibiting PI3K\/AKT\/NF-\u03baB Activation"],"prefix":"10.1016","volume":"19","author":[{"given":"Yanqiong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangxiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Funeng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijie","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuyan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taixian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2019.12.023_bib1","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1093\/bib\/bbx017","article-title":"A review of network-based approaches to drug repositioning","volume":"19","author":"Lotfi Shahreza","year":"2018","journal-title":"Brief. Bioinform."},{"key":"10.1016\/j.omtn.2019.12.023_bib2","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1208\/s12248-012-9390-1","article-title":"Drug repurposing: far beyond new targets for old drugs","volume":"14","author":"Oprea","year":"2012","journal-title":"AAPS J."},{"key":"10.1016\/j.omtn.2019.12.023_bib3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1758-2946-5-30","article-title":"Drug repositioning: a machine-learning approach through data integration","volume":"5","author":"Napolitano","year":"2013","journal-title":"J.\u00a0Cheminform."},{"key":"10.1016\/j.omtn.2019.12.023_bib4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/bib\/bbv020","article-title":"A survey of current trends in computational drug repositioning","volume":"17","author":"Li","year":"2016","journal-title":"Brief. Bioinform."},{"key":"10.1016\/j.omtn.2019.12.023_bib5","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1039\/c3mb70554d","article-title":"Drug repositioning by applying \u2018expression profiles\u2019 generated by integrating chemical structure similarity and gene semantic similarity","volume":"10","author":"Tan","year":"2014","journal-title":"Mol. Biosyst."},{"key":"10.1016\/j.omtn.2019.12.023_bib6","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1089\/cmb.2011.0264","article-title":"Large-scale elucidation of drug response pathways in humans","volume":"19","author":"Silberberg","year":"2012","journal-title":"J.\u00a0Comput. Biol."},{"key":"10.1016\/j.omtn.2019.12.023_bib7","doi-asserted-by":"crossref","first-page":"7147039","DOI":"10.1155\/2016\/7147039","article-title":"A systematic framework for drug repositioning from integrated omics and drug phenotype profiles using pathway-drug network","volume":"2016","author":"Jadamba","year":"2016","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.omtn.2019.12.023_bib8","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra1001683","article-title":"Hepatocellular carcinoma","volume":"365","author":"El-Serag","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2019.12.023_bib9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.omtn.2019.12.023_bib10","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/hep.25670","article-title":"Fibrosis-dependent mechanisms of hepatocarcinogenesis","volume":"56","author":"Zhang","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.omtn.2019.12.023_bib11","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1002\/cam4.2108","article-title":"Traditional Chinese medicine as a cancer treatment: modern perspectives of ancient but advanced science","volume":"8","author":"Xiang","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.omtn.2019.12.023_bib12","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1017\/erm.2018.3","article-title":"What has traditional Chinese medicine delivered for modern medicine?","volume":"20","author":"Wang","year":"2018","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/j.omtn.2019.12.023_bib13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13020-018-0167-z","article-title":"Internationalization of traditional Chinese medicine: current international market, internationalization challenges and prospective suggestions","volume":"13","author":"Lin","year":"2018","journal-title":"Chin. Med."},{"key":"10.1016\/j.omtn.2019.12.023_bib14","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jhep.2014.03.009","article-title":"Targeted therapy of liver fibrosis\/cirrhosis and its complications","volume":"61","author":"Zhang","year":"2014","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.omtn.2019.12.023_bib15","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jchromb.2015.12.024","article-title":"Identification of compounds in an anti-fibrosis Chinese medicine (Fufang Biejia Ruangan pill) and its absorbed components in rat biofluids and liver by UPLC-MS","volume":"1026","author":"Dong","year":"2016","journal-title":"J.\u00a0Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.omtn.2019.12.023_bib16","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.3748\/wjg.v19.i32.5326","article-title":"Effects of Fufang Biejia Ruangan pills on hepatic fibrosis in\u00a0vivo and in\u00a0vitro","volume":"19","author":"Yang","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.omtn.2019.12.023_bib17","first-page":"1380","article-title":"Effect and mechanism of Fufang Biejia Ruangan tablet in prevention and treatment of rat hepatic fibrosis [in Chinese]","volume":"43","author":"Yang","year":"2018","journal-title":"J.\u00a0Guiyang Medical College"},{"key":"10.1016\/j.omtn.2019.12.023_bib18","first-page":"114","article-title":"Effects on serum levels of IL-6, IL-8 and TNF-\u03b1and protective effects of liver injury by entecavir and Biejia Ruangan tablets in hepatitis B patients","volume":"18","author":"Chai","year":"2016","journal-title":"Liaoning Zhongyiyao Daxue Xuebao"},{"issue":"D1","key":"10.1016\/j.omtn.2019.12.023_bib19","doi-asserted-by":"crossref","first-page":"D976","DOI":"10.1093\/nar\/gky987","article-title":"ETCM: an encyclopaedia of traditional Chinese medicine","volume":"47","author":"Xu","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2019.12.023_bib20","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11523-017-0484-7","article-title":"Sorafenib: a review in hepatocellular carcinoma","volume":"12","author":"Keating","year":"2017","journal-title":"Target. Oncol."},{"key":"10.1016\/j.omtn.2019.12.023_bib21","doi-asserted-by":"crossref","first-page":"212533","DOI":"10.7573\/dic.212533","article-title":"Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications","volume":"7","author":"Personeni","year":"2018","journal-title":"Drugs Context"},{"key":"10.1016\/j.omtn.2019.12.023_bib22","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1038\/sj.onc.1209706","article-title":"Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K\/Akt\/NF-\u03baB signal transduction pathway","volume":"25","author":"Cheng","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.omtn.2019.12.023_bib23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s13046-018-0908-y","article-title":"HSCs-derived COMP drives hepatocellular carcinoma progression by\u00a0activating MEK\/ERK and PI3K\/AKT signaling pathways","volume":"37","author":"Li","year":"2018","journal-title":"J.\u00a0Exp. Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2019.12.023_bib24","doi-asserted-by":"crossref","first-page":"6706","DOI":"10.1038\/sj.onc.1209933","article-title":"Transcriptional regulation via the NF-\u03baB signaling module","volume":"25","author":"Hoffmann","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.omtn.2019.12.023_bib25","doi-asserted-by":"crossref","first-page":"e2688","DOI":"10.1038\/cddis.2017.18","article-title":"Hydrogen sulfide promotes autophagy of hepatocellular carcinoma cells through the PI3K\/Akt\/mTOR signaling pathway","volume":"8","author":"Wang","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.omtn.2019.12.023_bib26","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2174\/1389450117666151209120831","article-title":"Biology, epidemiology, clinical aspects of hepatocellular carcinoma and the role of sorafenib","volume":"17","author":"Mazzoccoli","year":"2016","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.omtn.2019.12.023_bib27","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1053\/j.gastro.2011.03.006","article-title":"Targeted therapies for hepatocellular carcinoma","volume":"140","author":"Villanueva","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.omtn.2019.12.023_bib28","first-page":"657","article-title":"Purinergic receptors in cancer and inflammation: from Rudolph Virchow to Geoff Burnstock","volume":"10","author":"Di Virgilio","year":"2014","journal-title":"Purinergic Signal"},{"key":"10.1016\/j.omtn.2019.12.023_bib29","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00432-017-2364-z","article-title":"Hepatic inflammation-fibrosis-cancer axis in the rat hepatocellular carcinoma induced by diethylnitrosamine","volume":"143","author":"Ding","year":"2017","journal-title":"J.\u00a0Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.omtn.2019.12.023_bib30","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41419-017-0175-4","article-title":"HMG-box transcription factor 1: a positive regulator of the G1\/S transition through the Cyclin-CDK-CDKI molecular network in nasopharyngeal carcinoma","volume":"9","author":"He","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.omtn.2019.12.023_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2018.10.012","article-title":"miR-202-3p regulates Sertoli cell proliferation, synthesis function, and apoptosis by targeting LRP6 and cyclin D1 of Wnt\/\u03b2-catenin signaling","volume":"14","author":"Yang","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"D1","key":"10.1016\/j.omtn.2019.12.023_bib32","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2019.12.023_bib33","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.nano.2018.09.002","article-title":"Galactosylated chitosan triptolide nanoparticles for overcoming hepatocellular carcinoma: enhanced therapeutic efficacy, low toxicity, and validated network regulatory mechanisms","volume":"15","author":"Zhang","year":"2019","journal-title":"Nanomedicine (Lond.)"},{"key":"10.1016\/j.omtn.2019.12.023_bib34","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0031-3203(94)E0043-K","article-title":"Image thresholding by minimizing the measures of fuzziness","volume":"28","author":"Huang","year":"1995","journal-title":"Pattern Recognit."},{"key":"10.1016\/j.omtn.2019.12.023_bib35","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3390\/v11020165","article-title":"QuantIF: an ImageJ macro to automatically determine the percentage of infected cells after immunofluorescence","volume":"11","author":"Handala","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.omtn.2019.12.023_bib36","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41419-018-0293-7","article-title":"Identification of a novel microRNA-mRNA regulatory biomodule in human prostate cancer","volume":"9","author":"Zhang","year":"2018","journal-title":"Cell Death Dis."}],"container-title":["Molecular Therapy - Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253120300032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253120300032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T02:12:47Z","timestamp":1715998367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253120300032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":36,"alternative-id":["S2162253120300032"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2019.12.023","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Discovery of Clinically Approved Formula FBRP for Repositioning to Treat HCC by Inhibiting PI3K\/AKT\/NF-\u03baB Activation","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2019.12.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s).","name":"copyright","label":"Copyright"}]}}